# FIZE Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/fize-medical

- Industry: Medical Devices & Equipment
- Headquarters: Modi'in-Maccabim-Re'ut, Israel
- Website: www.fizemedical.com
- Total disclosed funding: $41M
- Latest round: Series B (Sep 17, 2026)
- Investors on record: 5

## About

Based in Israel, with operations in the United States, was founded in 2014, by founder Noam Levine while Dror Zerem serves as CEO as of September 2026, FIZE Medical Ltd., develops solutions for monitoring vital signs using urine. In September 2026, FIZE MEDICAL Ltd. raised USD 20 million in series B funding from unspecified investors. In September 2026, FIZE MEDICAL Ltd. raised USD 20 million in series B funding co-led by Asahi Kasei Medical Co., Ltd. and Rapha Capital Management.

FIZE offers various medical devices, such as iUO, iUO PLUS, iUO DUOFLO, FIZE kUO PLUS, and FIZE dUO, that allow nursing and nursing aide staff to measure and record urine output and send automatic warnings to doctors and residents when the catheter becomes clogged or when urine production falls below particular trigger levels. These devices also improve the early diagnosis and treatment of acute kidney injury (AKI), sepsis, and other critical events that require early detection to achieve the best outcomes for patients. In addition to urine outflow management, the company offers advanced non-invasive, real-time urinalysis, hematuria and infection monitoring, and fluid inflow management.

FIZE Medical Ltd. generates revenue through the development, manufacture, and sale of real-time urine output monitoring systems and fluid management solutions for critical care patients. The company provides proprietary medical devices, clinical monitoring technologies, and associated healthcare solutions to hospitals and healthcare providers to support precision fluid management and kidney function monitoring in intensive care settings.

The company plans to utilize September 2026 funding to accelerate the development of next-generation FIZE Optima platform, which provides AI-driven prediction and treatment guidance for fluid management in critically ill patients and expansion of commercial activities, which includes broader distribution of its products in Europe.

## Funding rounds

- Series B, Sep 17, 2026, $20M — Rapha Capital Management, Asahi Kasei Medical Co., Ltd.
- Series A, Dec 20, 2024, $14M — Rapha Capital Management, eHealth Ventures, Valitas VC
- Series A, Apr 6, 2021, $5.3M — Rapha Capital Management, Mendham Investment Group
- Series A, May 4, 2020, $2M — Rapha Capital Management

## Investors

- Rapha Capital Management (https://capitalatlas.ai/funds/rapha-capital-management) — Series A, Series B
- Mendham Investment Group (https://capitalatlas.ai/funds/mendham-investment-group) — Series A
- eHealth Ventures (https://capitalatlas.ai/funds/ehealth-ventures) — Series A
- Valitas VC — Series A
- Asahi Kasei Medical Co., Ltd. — Series B